Atypical parkinsonism (PSP, MSA, CBD)
Parkinson-plus syndromes · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A group of neurodegenerative parkinsonian syndromes including progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration, distinguished from Parkinson's disease by early falls, poor levodopa response, autonomic failure and additional neurological signs. Prognosis is worse and management largely supportive.
Red flags
- Early recurrent falls within the first year
- Severe autonomic failure (syncope, marked postural drop)
- Rapid progression and early dysphagia
- Aspiration or respiratory compromise
- Stridor in MSA (airway risk)
Assessment
Differential diagnosis
- Idiopathic Parkinson's disease
- Dementia with Lewy bodies
- Vascular parkinsonism
- Drug-induced parkinsonism
- Normal pressure hydrocephalus
- Wilson's disease (younger patients)
Investigations
- MRI brain (hummingbird sign in PSP, hot cross bun/putaminal changes in MSA)
- Levodopa challenge to assess responsiveness
- Autonomic function testing (lying/standing BP) for MSA
- Neuropsychometry for cognitive and apraxic features
- DaTscan if uncertain (abnormal in degenerative parkinsonism)
- Exclude reversible causes (drug history, copper studies in young)
Management
- Suspect atypical parkinsonism when early falls, poor levodopa response or additional signs are present
- Characterise the syndrome: vertical gaze palsy and early falls (PSP), autonomic failure and cerebellar/pyramidal signs (MSA), asymmetric apraxia and alien limb (CBD)
- Perform a formal levodopa trial before concluding non-responsiveness
- Image to support the diagnosis and exclude mimics
- Treat orthostatic hypotension and bladder dysfunction in MSA
- Provide early falls prevention and multidisciplinary therapy
- Manage dysphagia and communication with speech and language therapy
- Discuss prognosis and advance care planning early
- Avoid antipsychotics where possible; manage behavioural symptoms carefully
- Refer to palliative care as disease progresses
Drugs & doses
Levodopa/carbidopa trial up to 1000 mg levodopa/day before declaring non-response
Midodrine 2.5-10 mg PO TDS for orthostatic hypotension (MSA)
Fludrocortisone 0.1-0.2 mg PO daily for orthostatic hypotension
Botulinum toxin for focal dystonia or blepharospasm
Clonazepam 0.25-0.5 mg PO nocte for REM sleep behaviour disorder
Disposition
Outpatient neurology with multidisciplinary team. Early palliative care involvement and advance care planning given poor prognosis.
Complications & pitfalls
- Falls and fractures
- Aspiration pneumonia from dysphagia
- Severe orthostatic hypotension
- Cognitive decline and communication loss
- Reduced life expectancy (typically 5-9 years)
Exam pearls
- Early falls plus poor levodopa response is the classic clue to atypical parkinsonism
- Vertical supranuclear gaze palsy points to PSP; autonomic failure to MSA; alien limb/apraxia to CBD
- Nocturnal stridor in MSA signals airway risk
- Always give an adequate levodopa trial before labelling non-responsive
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.